Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives "Buy" Rating from HC Wainwright

Key Points

• HC Wainwright has reiterated a "Buy" rating for Ultragenyx Pharmaceutical's stock with a target price of $80.00, indicating a potential upside of 153.89%.
• The company's recent earnings report showed that Ultragenyx surpassed analysts' estimates with a revenue of $166.50 million and an earnings per share of ($1.17), a slight improvement from the previous year's EPS of ($1.52).
• Despite the positive ratings from several analysts, the stock has fluctuated recently with a current price around $31.51, significantly lower than the target prices set by analysts.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $80.00 target price on the biopharmaceutical company's stock. HC Wainwright's price target would suggest a potential upside of 163.94% from the stock's previous close.

Several other research firms have also recently weighed in on RARE. Guggenheim reaffirmed a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wedbush lowered their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research note on Monday, July 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. Canaccord Genuity Group lowered their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, William Blair started coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price on the stock. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE traded down $0.92 on Tuesday, hitting $30.31. 1,391,015 shares of the company were exchanged, compared to its average volume of 1,305,561. The company's 50 day moving average price is $29.88 and its 200-day moving average price is $34.53. The firm has a market capitalization of $2.92 billion, a P/E ratio of -5.48 and a beta of 0.21. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business's revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,450 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company's stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares of the company's stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its position in Ultragenyx Pharmaceutical by 28.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock worth $116,559,000 after purchasing an additional 706,519 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Ultragenyx Pharmaceutical by 81.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after purchasing an additional 965,919 shares during the period. Federated Hermes Inc. boosted its position in Ultragenyx Pharmaceutical by 0.3% during the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock worth $74,419,000 after purchasing an additional 5,400 shares during the period. Geode Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock worth $62,291,000 after purchasing an additional 66,394 shares during the period. Finally, Deutsche Bank AG boosted its position in Ultragenyx Pharmaceutical by 0.5% during the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock worth $61,611,000 after purchasing an additional 8,385 shares during the period. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.